Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Assumptions
Chapter 2. Executive Summary
2.1. Global Parkinson’s Disease Therapeutics Market Portraiture
2.1.1. Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.1.2. Global Parkinson’s Disease Therapeutics Market, by Geography, 2017 (Value %)
Chapter 3. Parkinson’s Disease Therapeutics: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape: Global Parkinson’s Disease Therapeutics Market, by Key Players, 2017
Chapter 4. Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Dopamine Agonists
4.3. Levodopa/ Carbidopa
4.4. Anticholinergic Drugs
4.5. Monoamine Oxidase B (MAO-B) Inhibitors
4.6. Catechol-O-Methyltransferase (COMT) Inhibitors
4.7. Adenosine A2 Receptor Antagonist
4.8. Pipeline Candidates: Overview
4.8.1. Phase III (Market estimations by 2026)
4.8.1.1. APL-130277 (Cynapsus Therapeutics-Sunovion)
4.8.1.2. Accordion Pill Carbidopa/Levodopa (Intec Pharma)
4.8.1.3. P2B-001 (Pharma Two B)
4.8.1.4. ND0612H (Neuroderm)
4.8.2. Phase II & I (Tabular Information)
Chapter 5. Global Parkinson’s Disease Therapeutics Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.2.1. North America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.3.1. Europe Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Parkinson’s Disease Therapeutics Market Analysis , 2016 – 2026 (US$ Mn)
5.4.1. Asia Pacific Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of APAC
5.5. Latin America Parkinson’s Disease Therapeutics Market Analysis , 2016 – 2026 (US$ Mn)
5.5.1. Latin America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.6.1. MEA Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Abbvie, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Biogen, Inc.
6.3. Boehringer Ingelheim GmbH
6.4. F. Hoffman-La Roche
6.5. GlaxoSmithKline Plc.
6.6. H. Lundbeck A/S
6.7. Impax Labs, Inc.
6.8. Newron Pharmaceuticals SpA
6.9. Novartis AG
6.10. Orion Corporation
6.11. Teva Pharmaceutical Industries Ltd.
6.12. UCB S.A.
List of Figures
FIG. 1 Parkinson’s Disease Therapeutics: Market Segmentation
FIG. 2 Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2017 (US$ Mn)
FIG. 3 Global Parkinson’s Disease Therapeutics Market, by Geography, 2017 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2017
FIG. 5 Market Competition Landscape, by Key Players, 2017
FIG. 6 Global Dopamine Agonists Market, 2016 – 2026 (US$ Mn)
FIG. 7 Global Levodopa/ Carbidopa Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Anticholinergic Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global Monoamine Oxidase B (MAO-B) Inhibitors Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Catechol-O-Methyltransferase (COMT) Inhibitors Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Adenosine A2 Receptor Antagonist Market, 2016 – 2026 (US$ Mn)
FIG. 12 U.S. Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 13 Canada Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 14 U.K. Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 15 Germany Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 16 Rest of Europe Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 17 Japan Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 18 China Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Asia Pacific Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 20 Brazil Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 21 Mexico Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Latin America Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 23 GCC Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
List of Tables
Table 1 Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 2 North America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 3 North America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 4 Europe Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 5 Europe Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 6 Asia Pacific Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 7 Asia Pacific Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 8 Latin America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 9 Latin America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 10 Middle East and Africa Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 11 Middle East and Africa Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 12 Abbvie,Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 13 Biogen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 14 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 15 F. Hoffman-La Roche: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 16 GlaxoSmithKline Plc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 17 H. Lundbeck A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 18 Impax Labs, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 19 Newron Pharmaceuticals SpA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 21 Orion Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 Teva Pharmaceutical Industries Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 23 UCB S.A. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)